
	Press Releases
	Press Releases en Français
	Calendar
	Archives 2003-2005

Press Releases

ENGLISH	04/30/08	Q1 2008: significant progress at an international level
ENGLISH	04/21/08	BioAlliance Pharma announces preliminary results from the pivotal US phase III trial for Loramyc™
ENGLISH	04/14/08	BioAlliance Pharma reports the availability of its 2007 Reference Document
ENGLISH	04/14/08	BioAlliance Pharma announces participation in the SmallCap Event On April 21st and 22nd in Paris, ‘hotel Hilton’
ENGLISH	03/31/08	BioAlliance Pharma expands its Loramyc™ franchise by signing a South East Asia deal worth up to $12 million with the leading Korean pharma company Handok
ENGLISH	03/26/08	BioAlliance Pharma receives market approval for Loramyc® in Germany, Belgium and Luxemburg
ENGLISH	02/29/08	BioAlliance Pharma announces its full-year results for 2007
ENGLISH	02/25/08	BioAlliance Pharma to pursue its strategy for the targeted acquisition of complementary products following the announcement of the discontinuation of Immtech Pharmaceuticals' pafuramidine program
ENGLISH	01/30/08	BioAlliance Pharma announces a 786% increase in revenues for the fourth quarter of 2007
ENGLISH	01/21/08	BioAlliance Pharma publishes its 2008 financial calendar and announces the opening of its European corporate headquarters
ENGLISH	01/09/08	BioAlliance Pharma receives market approval for Loramyc® in the United Kingdom and Denmark
ENGLISH	12/27/07	BioAlliance Pharma provides information on a press release received from Immtech Pharmaceuticals
ENGLISH	12/12/07	BioAlliance Pharma reinforces its new therapeutic entity patent portfolio
ENGLISH	12/05/07	BioAlliance Pharma acquires the European commercialization rights to pafuramidine for the treatment of Pneumocystis carinii pneumonia
ENGLISH	11/28/07	BioAlliance Pharma accelerates its international clinical research program. Extension to the United States of the acyclovir Lauriad® Phase III trial
ENGLISH	11/16/07	BioAlliance Pharma completes patient enrolment ahead of schedule for its pivotal phase III clinical trial of Loramyc® in the USA for the treatment of oropharyngeal candidiasis
ENGLISH	11/12/07	BioAlliance Pharma announces its participation in the Natixis Securities MidCap Healthcare Conference
ENGLISH	10/29/07	BioAlliance Pharma’s New Entity, AMEP, shows anti-angiogenic and antiproliferative activity in vitro and in vivo
ENGLISH	10/29/07	BioAlliance Pharma announces Q3 2007 results Specialty pharma announces very strong growth in revenues and cash
ENGLISH	10/22/07	BioAlliance Pharma will present promising in vivo results for a New Entity at 15th congress of European Society of Gene and Cell Therapy
ENGLISH	09/25/07	Results presented at ECCO 2007 further confirm the clinical efficacy of BioAlliance Pharma’s antifungal, particularly in populations with high risk of candidiasis
ENGLISH	09/17/07	Scientific results presented at ICAAC demonstrate the well-differentiated profile and broad spectrum of BioAlliance Pharma’s antifungal
ENGLISH	09/14/07	BioAlliance Pharma appoints Professor Christian Auclair Chief Scientific Officer
ENGLISH	09/10/07	BioAlliance Pharma takes part in Paris MidCap Event September 17-18
ENGLISH	09/04/07	BioAlliance Pharma announces first half 2007 results Significant progress towards company growth
ENGLISH	09/04/07	BioAlliance Pharma launches its first product, Loramyc®, on the French market
ENGLISH	07/26/07	BioAlliance Pharma announces fund raising of €40 million by private placement This operation will foster an accelerated growth of the company
ENGLISH	07/19/07	BioAlliance Pharma announces consolidated revenues for Q2 2007
ENGLISH	07/03/07	Bioalliance Pharma licenses Loramyc™ U.S. commercialization rights to Par Pharmaceutical in a $65 million deal
ENGLISH	06/12/07	BioAlliance Pharma announces acceptance of EUR 4 per day pricing for Loramyc® on the French market pending publication in France’s Journal Officiel
ENGLISH	06/07/07	BioAlliance Pharma establishes new subsidiary, SpeBio, to sell Loramyc® in Europe
ENGLISH	04/26/07	BioAlliance Pharma announces consolidated revenues for Q1 2007
ENGLISH	03/08/07	BioAlliance Pharma sets up European Joint Venture with Spepharm to sell Loramyc®
ENGLISH	03/01/07	BioAlliance announces financial results for 2006
ENGLISH	02/05/07	BioAlliance Pharma announces 2006 consolidated revenues
ENGLISH	02/01/07	BioAlliance Pharma raises free float to 40 per cent of capital
ENGLISH	12/14/06	BioAlliance Pharma announces Phase II/III trial for its primary liver cancer treatment, doxorubicin Transdrug®
ENGLISH	11/21/06	BioAlliance Pharma appoints Nicolas Fellmann as CFO
ENGLISH	11/15/06	BioAlliance Pharma announces third quarter 2006 consolidated revenues
ENGLISH	10/13/06	BioAlliance Pharma receives marketing authorisation for its first product, Loramyc®
ENGLISH	09/27/06	Half-year 2006 results — Major progress in clinical programs
ENGLISH	09/19/06	BioAlliance Pharma announces final results of its doxorubicin Transdrug® Phase I/II clinical trial for primary liver cancer
ENGLISH	07/17/06	BioAlliance Pharma strengthens international capabilities in key legal, IP, and regulatory departments
ENGLISH	06/30/06	BioAlliance Pharma announces preliminary results of its Doxorubicin Transdrug® Phase I/II clinical trial for primary liver cancer
ENGLISH	06/26/06	BioAlliance Pharma Strengthens Operational Management ahead of Loramyc® Launch
ENGLISH	06/21/06	BioAlliance Pharma Presents at First Ever Piper Jaffray London Healthcare Conference
ENGLISH	05/16/06	BioAlliance Pharma boosts business development operations in Europe and US
ENGLISH	05/16/06	BioAlliance Pharma starts pivotal Phase III clinical trial in the US of Loramyc® treatment for oropharyngeal candidiasis
ENGLISH	05/04/06	BioAlliance Pharma Establishes Sales & Marketing Subsidiary in preparation for Launch of Loramyc®
ENGLISH	03/31//06	BioAlliance Pharma Announces 2005 Financial Results
ENGLISH	01/24//06	BioAlliance Pharma Appoints Former GlaxoSmithKline Executive As Vice President Of Sales & Marketing
ENGLISH	01/17//06	Communication on the assignment of shares following a unilateral c ommitment to sell granted by Gilles Avenard
ENGLISH	01/10//06	ING Securities Bank (France), acting as stabilisation manager, gives notice of the stabilisation transactions carried out in connection with the initial public offering of the shares of BioAlliance Pharma.
ENGLISH	01/05/06	BioAlliance Pharma Names François Sarkozy as Vice-Chairman of its Supervisory Board